Montserrat Muñoz-Mateu

Author

Also Known As

A. Barnadas, Castillo, Oleguer, Ciruelos, E, García-Saenz, José Ángel, Giarratano, Tommaso, Hoadley, Katherine A., Jefferson Fabian Nieves Condoy, M Gutierrez Munoz, M Munoz, M Muñoz

618

Publications

9.7K

Citations

H-Index

Concepts

All Affiliations

Hospital Clínic de Barcelona Consorci Institut D'Investigacions Biomediques August Pi I Sunyer GEICAM – Spanish Breast Cancer Group Hospital General Universitario Gregorio Marañón Hospital Clínico Universitario de Valencia

About

Montserrat Muñoz-Mateu is an author at Hospital Clínic de Barcelona specializing in medicine, breast cancer, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	18	23	1.5K
2	Health Sciences	11	11	378
3	Engineering	3	3	149
4	Nursing	2	2	94
5	Biochemistry	1	1	17

Montserrat Muñoz-Mateu

Publications

4.6K

Citations

H-Index

Page 1

	Year	Citations
Frequency and spectrum of PIK3CA somatic mutations in breast cancer Olga Martínez‐Sáez, Núria Chic, Tomás Pascual, Breast Cancer Research	2020	357
HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial Antonio Llombart‐Cussac, Javier Cortés, Laia Paré, The Lancet Oncology Breast OncologyMedicinePathologyPathological Complete ResponseImmune Checkpoint Inhibitor	2017	329
Preoperative Staging of Large Primary Breast Cancer With [ <sup>18</sup> F]Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Compared With Conventional Imaging Procedures David Fuster, Joan Duch, Pilar Paredes, Journal of Clinical Oncology	2008	273
Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer Juan Miguel Cejalvo, Eduardo Martínez de Dueñas, Patricia Galván, Cancer Research	2017	239
Adjuvant Docetaxel for High-Risk, Node-Negative Breast Cancer Miguel Martín, Miguel Ángel Seguí, Antonio Antón, New England Journal of Medicine	2010	208
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial Aleix Prat, Cristina Saura, Tomás Pascual, The Lancet Oncology Breast OncologyMedicinePharmacologyGynecologyBreast Cancer	2019	191
Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy Aleix Prat, Aranzazu Fernández-Martínez, Katherine A. Hoadley, BMC Medicine	2015	156
Phase III Trial Evaluating the Addition of Bevacizumab to Endocrine Therapy As First-Line Treatment for Advanced Breast Cancer: The Letrozole/Fulvestrant and Avastin (LEA) Study Miguel Martín, Sibylle Loibl, Gϋnter von Minckwitz, Journal of Clinical Oncology	2015	132
c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value R. Molina, Judith Jo, Xavier Filella, Breast Cancer Research and Treatment Tumor BiologyBreast OncologyMedicineC-erbb-2 OncoproteinPathology	1998	125
A Single-Nucleotide Polymorphism in the Aromatase Gene Is Associated with the Efficacy of the Aromatase Inhibitor Letrozole in Advanced Breast Carcinoma Rámón Colomer, Mariano Monzó, Ignasi Tusquets, Clinical Cancer Research	2008	122

Page 1